132 related articles for article (PubMed ID: 35166266)
1. Validation of the IASLC Residual Tumor Classification in Patients With Stage III-N2 Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiotherapy Followed By Surgery.
Lee J; Lee J; Hong YS; Lee G; Kang D; Yun J; Jeon YJ; Shin S; Cho JH; Choi YS; Kim J; Zo JI; Shim YM; Guallar E; Cho J; Kim HK
Ann Surg; 2023 Jun; 277(6):e1355-e1363. PubMed ID: 35166266
[TBL] [Abstract][Full Text] [Related]
2. A Validation Study of the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients With pN2 NSCLC.
Yun JK; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
J Thorac Oncol; 2021 May; 16(5):817-826. PubMed ID: 33607310
[TBL] [Abstract][Full Text] [Related]
3. Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.
Osarogiagbon RU; Faris NR; Stevens W; Fehnel C; Houston-Harris C; Ojeabulu P; Akinbobola OA; Lee YS; Ray MA; Smeltzer MP
J Thorac Oncol; 2020 Mar; 15(3):371-382. PubMed ID: 31783180
[TBL] [Abstract][Full Text] [Related]
4. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer.
Edwards JG; Chansky K; Van Schil P; Nicholson AG; Boubia S; Brambilla E; Donington J; Galateau-Sallé F; Hoffmann H; Infante M; Marino M; Marom EM; Nakajima J; Ostrowski M; Travis WD; Tsao MS; Yatabe Y; Giroux DJ; Shemanski L; Crowley J; Krasnik M; Asamura H; Rami-Porta R;
J Thorac Oncol; 2020 Mar; 15(3):344-359. PubMed ID: 31731014
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of the Proposed Residual Tumor Classification in Patients With NSCLC After Sleeve Lobectomy.
Chen T; Zhong Y; Wen J; Deng J; She Y; Zhu Y; Chen Q; Wu C; Hou L; Jiang L; Chen C
JTO Clin Res Rep; 2023 Oct; 4(10):100574. PubMed ID: 37822700
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification to Upgrade Extracapsular Extension of Tumor in Nodes From R0 to Incomplete Resection.
Xie H; Dai C; Gu C; Zhao S; Xu L; Wang F; Gao J; Su H; Wu J; She Y; Ren Y; Wu C; Chen C
J Thorac Oncol; 2024 Jan; 19(1):130-140. PubMed ID: 37567388
[TBL] [Abstract][Full Text] [Related]
7. Prognostic evaluation of the proposed residual tumor classification in a Chinese non-small cell lung cancer population.
Ren Y; She Y; Tang H; Deng J; Jiang G; Wu C; Zhu Y; Zheng H; Chen C
J Surg Oncol; 2022 May; 125(6):1061-1070. PubMed ID: 35099810
[TBL] [Abstract][Full Text] [Related]
8. Residual tumor descriptors proposed by the International Association for the Study of Lung Cancer may not be applicable to stage I and ground-glass opacity-featured non-small cell lung cancer.
Wen Z; Fu F; Zhao Y; Gao Z; Han H; Li H; Ye T; Hu H; Sun Y; Li Y; Zhang Y; Chen H
Transl Lung Cancer Res; 2023 Nov; 12(11):2157-2168. PubMed ID: 38090514
[TBL] [Abstract][Full Text] [Related]
9. Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
Gagliasso M; Migliaretti G; Ardissone F
Lung Cancer; 2017 Sep; 111():124-130. PubMed ID: 28838382
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Uncertain Resection for Overall Survival in Non-small Cell Lung Cancer.
Kadomatsu Y; Nakamura S; Ueno H; Goto M; Ozeki N; Fukumoto K; Fukui T; Suzuki Y; Chen-Yoshikawa TF
Ann Thorac Surg; 2022 Oct; 114(4):1262-1268. PubMed ID: 34474024
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
[TBL] [Abstract][Full Text] [Related]
12. Change of junctions between stations 10 and 4 in the new International Association for the Study of Lung Cancer Lymph Node Map: a validation study from a single, tertiary referral hospital experience.
Lee S; Lee HY; Lee KS; Yie M; Zo J; Shim YM; Han J; Ahn JH
Chest; 2015 May; 147(5):1299-1306. PubMed ID: 25275253
[TBL] [Abstract][Full Text] [Related]
13. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
14. Reclassifying the International Association for the Study of Lung Cancer Residual Tumor Classification According to the Extent of Nodal Dissection for NSCLC: One Size Does Not Fit All.
Lee J; Hong YS; Cho J; Lee J; Lee G; Kang D; Yun J; Jeon YJ; Shin S; Cho JH; Choi YS; Kim J; Zo JI; Shim YM; Guallar E; Kim HK
J Thorac Oncol; 2022 Jul; 17(7):890-899. PubMed ID: 35462086
[TBL] [Abstract][Full Text] [Related]
15. Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer.
Andrews WG; Louie BE; Castiglioni M; Dhamija A; Farivar AS; Chansky J; White PT; Aye RW; Vallières E; Bograd AJ
Ann Thorac Surg; 2022 Aug; 114(2):394-400. PubMed ID: 34890568
[TBL] [Abstract][Full Text] [Related]
16. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
18. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry.
Ou SH; Zell JA
J Thorac Oncol; 2008 Mar; 3(3):216-27. PubMed ID: 18317063
[TBL] [Abstract][Full Text] [Related]
19. Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
Ma Q; Liu D; Guo Y; Shi B; Song Z; Tian Y
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):342-8. PubMed ID: 20677562
[TBL] [Abstract][Full Text] [Related]
20. Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
Lee J; Kim HK; Park BJ; Cho JH; Choi YS; Zo JI; Shim YM; Pyo H; Ahn YC; Ahn JS; Ahn MJ; Park K; Kim J
Lung Cancer; 2018 Jan; 115():89-96. PubMed ID: 29290268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
